Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released
SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today released details about its upcoming COVID-19 Pipeline Update call and webcast on October 13th, 2020.
For registered analysts and pre-certified participants:
Toll Free Number: (833) 665-0715
For other participants (webcast, with ability to submit questions during the session):
Management participants will include:
R&D Day Agenda:
• Strategic Outlook (Dr. Henry Ji)
• Therapeutic Pipeline – Clinical Stage (Management)
• Therapeutic Pipeline – IND enabling Stage (Management)
• Therapeutic Discovery (Dr. Henry Ji)
• Diagnostics (Management)
About Sorrento Therapeutics, Inc.
Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ("RTX"), and ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a phase 1B trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. ZTlido® was approved by the FDA on February 28, 2018.
For more information, visit www.sorrentotherapeutics.com
Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.
ZTlido® is a trademark owned by Scilex Pharmaceuticals Inc.
IoT Security Against Global Cybercrime
#TECHSUPERSHOW Conference Party